Yosemite — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Eureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell-based therapies to treat solid tumors and other cancers.
BiotechHealthtechEmeryville, US
Cheng Liu(Executive Officer, Director)
BoardSandy Chau(Director)Hsing Kung(Director)Qiushi Fu(Director)Chih-Kai Cheng(Director)Michael Cannon(Director)
Board seatReed Jobs· per SEC Form D · $20M raise · filed May 2023
Co-investorsAcorn Pacific Ventures
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Executive Officer)Derek Jantz(Executive Officer)inCharles Gersbach(Director)inJohn McHutchison(CEO, Chairman of the Board)Dan McHugh(Executive Officer, Director)Blythe Sather(Executive Officer)
Co-investorsDuke Capital PartnersMission BiocapitalNew Enterprise Associates (NEA)Hatteras Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.